Lars Erik Kristensen1, Tanja S Jørgensen1, Robin Christensen1, Henrik Gudbergsen1, Lene Dreyer1,2, Christine Ballegaard1, Lennart T H Jacobsson3, Vibeke Strand4, Philip J Mease5, Jakob Kjellberg6. 1. The Parker Institute, Copenhagen University Hospital, Bispebjerg & Frederiksberg, Denmark. 2. Gentofte Hospital, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Hellerup, Denmark. 3. Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 4. Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA. 5. Swedish Medical Center and University of Washington, Seattle, Washington, USA. 6. Danish Institute for Local and Regional Government Research, Copenhagen, Denmark.
Abstract
OBJECTIVES: To comprehensively study the comorbidities, healthcare and public transfer (allowance) costs in patients with psoriatic arthritis (PsA) before and after diagnosis. METHODS: Nationwide cohort study, using data from Danish registries from January 1998 through December 2014. A total of 10 525 patients with PsA and 20 777 matched general population comparator (GPC) subjects were included. Societal costs, employment status and occurrence of comorbidities in patients with PsA both before and after diagnosis were compared with GPC subjects. RESULTS: At baseline, patients with PsA had significantly more comorbidities, including cardiovascular disease (OR 1.70 95% CI 1.55 to 1.86), respiratory diseases (OR 1.73 95% CI 1.54 to 1.96) and infectious diseases (OR 2.03 95% CI 1.69 to 2.42) compared with GPC subjects. At all time points, patients with PsA had higher total healthcare and public transfer costs; they also had lower income (p<0.001) and incurred a net average increased societal cost of €10 641 per patient-year compared with GPC subjects following diagnosis. The relative risk (RR) for being on disability pension 5 years prior to PsA diagnosis was 1.36 (95% CI 1.24 to 1.49) compared with GPC subjects. The RR increased to 1.60 (95% CI 1.49 to 1.72) at the time of diagnosis and was 2.69 (95% CI 2.40 to 3.02) 10 years after diagnosis, where 21.8% of the patients with PsA received disability pension. CONCLUSIONS: Our findings are suggestive of health inequity for patients with PsA and call for individual preventive measures and societal action. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
OBJECTIVES: To comprehensively study the comorbidities, healthcare and public transfer (allowance) costs in patients with psoriatic arthritis (PsA) before and after diagnosis. METHODS: Nationwide cohort study, using data from Danish registries from January 1998 through December 2014. A total of 10 525 patients with PsA and 20 777 matched general population comparator (GPC) subjects were included. Societal costs, employment status and occurrence of comorbidities in patients with PsA both before and after diagnosis were compared with GPC subjects. RESULTS: At baseline, patients with PsA had significantly more comorbidities, including cardiovascular disease (OR 1.70 95% CI 1.55 to 1.86), respiratory diseases (OR 1.73 95% CI 1.54 to 1.96) and infectious diseases (OR 2.03 95% CI 1.69 to 2.42) compared with GPC subjects. At all time points, patients with PsA had higher total healthcare and public transfer costs; they also had lower income (p<0.001) and incurred a net average increased societal cost of €10 641 per patient-year compared with GPC subjects following diagnosis. The relative risk (RR) for being on disability pension 5 years prior to PsA diagnosis was 1.36 (95% CI 1.24 to 1.49) compared with GPC subjects. The RR increased to 1.60 (95% CI 1.49 to 1.72) at the time of diagnosis and was 2.69 (95% CI 2.40 to 3.02) 10 years after diagnosis, where 21.8% of the patients with PsA received disability pension. CONCLUSIONS: Our findings are suggestive of health inequity for patients with PsA and call for individual preventive measures and societal action. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: L Degli Esposti; V Perrone; D Sangiorgi; D Alessandrini; S Buda; F Cantini; E Mazzini; C Toma; F De Solda Journal: Patient Prefer Adherence Date: 2019-01-22 Impact factor: 2.711
Authors: Arthur Kavanaugh; Kim Papp; Alice B Gottlieb; Elke M G J de Jong; Soumya D Chakravarty; Shelly Kafka; Wayne Langholff; Kamyar Farahi; Bhaskar Srivastava; Jose U Scher Journal: BMC Rheumatol Date: 2018-09-29
Authors: Tanja Schjødt Jørgensen; Jens Jørgen Lykkegaard; Annette Hansen; Heidi Morsø Schrøder; Betina Stampe; Anne-Marie Tetsche Sweeney; Bente Appel Esbensen; Bianca Bech; Katja Christensen; Ellen Friis-Mikkelsen; Henrik Røgind; Tine Lundbak; Peter C Taylor; Ingemar F Petersson; Eva Ejlersen Wæhrens; Jakob Kjellberg; Henrik Gudbergsen; Lars Erik Kristensen Journal: BMJ Open Date: 2018-10-23 Impact factor: 2.692